Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

EQ vs AKTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EQ Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

EQ Overall Winner 6-Pillar Tally: EQ 5 – 0 AKTX (1 Tie) Matrix Metrics: EQ 5 – 3 AKTX

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EQ carries a Unified Composite Score of 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin), whereas AKTX carries 53.0/100 (HOLD) at $6.71 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile AKTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EQ vs AKTX
EQ NASDAQ Head-to-Head Winner
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49
AKTX NASDAQ
Akari Therapeutics plc ADR (0.01 USD)
Pharmaceutical Preparations
$6.71
+0.9% 1D
Market Cap $16.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 81.68β · 145% Vol
Unified Composite Score
53.0 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.9%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $7.57 · SMA50: $8.56

6-Pillar Scorecard Institutional Category Breakdown (EQ 5 – 0 AKTX)

Columns: Metric · EQ · AKTX
1. Valuation Multiples EQ
Forward P/E 1.5x N/M
Trailing P/E 1.5x N/M
PEG Ratio N/M N/M
EV / Revenue 7.7x N/M
2. Growth & Scale EQ
Revenue Growth (YoY) -52.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.4M N/A
Market Cap $90.6M $16.3M
3. Profitability & Quality EQ
Gross Margin 100.0% N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -59.0% -146.3%
4. Balance Sheet & Cash Flow EQ
Cash Generation (TTM) -$20M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $57M Net Cash $7.66 Book/Sh · -146.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EQ
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 261.3% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EQ (5) vs AKTX (3)
Institutional Metric EQ AKTX Criterion Row Edge
Market Capitalization
Scale
$90.6M $16.3M Larger Scale EQ
Trailing P/E Ratio
Valuation
1.5x N/M Lower Multiple EQ
Forward P/E Ratio
Valuation
1.5x N/M Lower Multiple EQ
Revenue Growth (YoY)
Growth
-52.3% +0.0% Higher Growth AKTX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-59.0% -146.3% Higher ROE EQ
52-Week Range Position
Momentum
11% ($1–$4) 23% ($0–$29) Stronger Trend AKTX
Beta / 30D Volatility
Risk Regime
1.53β · 93% Vol 81.68β · 145% Vol Lower Realized Risk EQ
Unified Institutional Score
Composite Signal
48.0 / 100 (HOLD) 53.0 / 100 (HOLD) Higher Composite AKTX
Trailing 12M Revenue (USD)
Operating Scale
$4.4M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($57M Net Cash) N/A ($7.66 Book/Sh · -146.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EQ +2.27 pp
EQ: -21.13% · AKTX: -23.4%
3M Horizon AKTX +37.0 pp
EQ: -51.52% · AKTX: -14.52%
6M Horizon AKTX +79.86 pp
EQ: -49.32% · AKTX: +30.54%
1Y Horizon AKTX +1151.65 pp
EQ: +12.0% · AKTX: +1163.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs AKTX. Trailing 12-month operating profitability (EQ 0.0% vs AKTX 0.0%) and valuation multiples (EQ 1.5x vs AKTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EQ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.4M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-59.0% · 1.5x
AKTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-146.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $16.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EQ vs AKTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EQ carries a Unified Composite Score of 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin), whereas AKTX carries 53.0/100 (HOLD) at $6.71 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. +0.0% YoY). Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile AKTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EQ leads the Growth & Scale pillar: EQ posts -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with AKTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EQ generates $4.4M in USD-normalized revenue versus N/A for AKTX. In operating R&D and SG&A reinvestment, EQ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKTX.

EQ screens cheaper on headline valuation multiples. EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin), whereas AKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EQ (-59.0% ROE) versus AKTX (-146.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk). By comparison, AKTX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (81.68β · 145% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.